.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XA03_Oxaliplatin.Oxaliplatin .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XA03_Oxaliplatin.Oxaliplatin| name: | Oxaliplatin |
| ATC code: | L01XA03 | route: | intravenous |
| n-compartments | 2 |
Oxaliplatin is a third-generation platinum-based antineoplastic agent primarily used in combination with fluoropyrimidines for the treatment of metastatic colorectal cancer. It is widely approved and utilized today as a component of regimens such as FOLFOX.
Pharmacokinetics reported in adult cancer patients receiving intravenous oxaliplatin. Typical dose 130 mg/m2 over 2 hours.
Mas-Fuster, MI, et al., & Nalda-Molina, R (2018). Population pharmacokinetics of oxaliplatin after intraperitoneal administration with hyperthermia in Wistar rats. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 119 22–30. DOI:10.1016/j.ejps.2018.04.004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29626594
Rietveld, PCS, et al., & Koolen, SLW (2024). Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 176 116820–None. DOI:10.1016/j.biopha.2024.116820 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38810398
Jiang, X, et al., & McLachlan, AJ (2008). Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. British journal of clinical pharmacology 65(3) 326–333. DOI:10.1111/j.1365-2125.2007.03040.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/17961191